Ovarian Cancer

被引:598
作者
Cho, Kathleen R. [1 ,2 ]
Shih, Ie-Ming [3 ]
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Johns Hopkins Med Inst, Dept Pathol, Div Gynecol Pathol, Baltimore, MD 21231 USA
基金
美国国家卫生研究院;
关键词
endometrioid; serous; genetics; mouse models; classification; COMPARATIVE GENOMIC HYBRIDIZATION; CLEAR-CELL CARCINOMA; BETA-CATENIN GENE; SEROUS BORDERLINE TUMORS; ACTIVATED PROTEIN-KINASE; DISTAL FALLOPIAN-TUBE; K-RAS PROTOONCOGENE; MICROSATELLITE INSTABILITY; EPITHELIAL TUMORS; LOW-GRADE;
D O I
10.1146/annurev.pathol.4.110807.092246
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Ovarian carcinomas are a heterogeneous group of neoplasms and are traditionally subclassified based on type and degree of differentiation. Although current clinical management of ovarian carcinoma largely fails to take this heterogeneity into account, it is becoming evident that each major histological type has characteristic genetic defects that deregulate specific signaling pathways in the tumor cells. Moreover, within the most common histological types, the molecular pathogenesis of low-grade versus high-grade tumors appears to be largely distinct. Mouse models of ovarian carcinoma have been developed that recapitulate many of the morphological features, biological behavior, and gene-expression patterns of selected subtypes of ovarian cancer. Such models will likely prove useful for studying ovarian cancer biology and for preclinical testing of molecularly targeted therapeutics, which may ultimately lead to better clinical outcomes for women with ovarian cancer.
引用
收藏
页码:287 / 313
页数:27
相关论文
共 147 条
[1]
WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium [J].
Acs, G ;
Pasha, T ;
Zhang, PJ .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (02) :110-118
[2]
HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma [J].
Afify, AM ;
Werness, BA ;
Mark, HFL .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1999, 66 (02) :163-169
[3]
Cl-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK) [J].
Allen, LF ;
Sebolt-Leopold, J ;
Meyer, MB .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :105-116
[4]
Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[5]
Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability [J].
Amemiya, S ;
Sekizawa, A ;
Otsuka, J ;
Tachikawa, T ;
Saito, H ;
Okai, T .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2004, 86 (03) :371-376
[6]
Arboleda MJ, 2003, CANCER RES, V63, P196
[7]
CHD5 is a tumor suppressor at human 1p36 [J].
Bagchi, Anindya ;
Papazoglu, Cristian ;
Wu, Ying ;
Capurso, Daniel ;
Brodt, Michael ;
Francis, Dailia ;
Bredel, Markus ;
Vogel, Hannes ;
Mills, Alea A. .
CELL, 2007, 128 (03) :459-475
[8]
Baldwin RL, 2000, CANCER RES, V60, P5329
[9]
Cyclin E deregulation alters the biologic properties of ovarian cancer cells [J].
Bedrosian, I ;
Lu, KH ;
Verschraegen, C ;
Keyomarsi, K .
ONCOGENE, 2004, 23 (15) :2648-2657
[10]
Origins and molecular pathology of ovarian cancer [J].
Bell, DA .
MODERN PATHOLOGY, 2005, 18 :S19-S32